Trial Radar

Study tracking how the body absorbs, processes and eliminates a single dose of ontunisertib using radioactive labelling in healthy men.

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal…

Phase I trial testing inavolisib alone and combined with standard breast cancer treatments in patients with PIK3CA-mutant tumours.

The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules…

ORIC-114 is being tested as a novel therapeutic agent either alone or combined with chemotherapy in patients with advanced solid tumors carrying EGFR or…

RG6496 is being tested in Huntington's disease gene carriers to assess its safety, tolerability, and how the body processes it.

Drug being tested: LY3962681, a novel investigational compound undergoing evaluation for safety, tolerability, and pharmacokinetic/pharmacodynamic properties in both healthy volunteers and Parkinson's disease patients…

What is being tested: A COPD self-management app designed to safely and accurately identify when patients are not receiving optimal inhaled therapy for their…

What is being tested: CTIM-76, a CLDN6-directed T cell-engaging bispecific antibody, is being evaluated in a Phase 1a/1b dose escalation and expansion study to…

What is being tested: Amivantamab (an EGFR/MET bispecific antibody) is being evaluated as monotherapy and in combination with pembrolizumab, paclitaxel, or pembrolizumab plus carboplatin…

What is being tested: Two different formulations of GSK3862995B, an investigational medicine, are being compared to evaluate their pharmacokinetics (absorption, distribution, metabolism, and elimination),…

A new experimental drug (GSK4528287) for inflammatory bowel disease is being tested in healthy volunteers for the first time to check safety and how…

Trial testing whether combining AZD5305 with hormone therapies is safe and effective for advanced prostate cancer.

Early-stage trial testing a new injection drug's safety, tolerability, and how the body processes it in patients with rheumatoid arthritis or lupus.

What is being tested: VB10.16 (therapeutic DNA vaccine) combined with pembrolizumab (PD-1 inhibitor) in patients with unresectable recurrent or metastatic HPV16-positive oropharyngeal head and…

Phase 1 trial testing dostarlimab, a new PD-1 immunotherapy antibody, for safety and effectiveness in advanced cancer patients.

Study comparing how the body processes nusinersen delivered via an implantable device versus lumbar puncture in spinal muscular atrophy patients.

Drug being tested: DNL921 is a novel investigational agent undergoing Phase 1/1b evaluation for safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and…

Treatment being tested: Cevostamab (a novel therapeutic agent) administered as monotherapy or in combination with established multiple myeloma regimens (pomalidomide/dexamethasone or daratumumab/dexamethasone) to evaluate…

Investigational Agent: NNC0537-1482 is a novel drug being evaluated for safety, tolerability, and pharmacological efficacy in heart failure patients—addressing an unmet therapeutic need in…

Early-stage trial testing a new antibody drug (cevostamab) alone or combined with existing treatments for hard-to-treat multiple myeloma.

ODM-208 showed acceptable safety in advanced prostate cancer patients, supporting further development of this new treatment.

Gene therapy AVB-101 delivered to the brain as one-time treatment for early-onset dementia caused by progranulin protein deficiency.

Early-stage study testing a new cancer drug (tuvusertib) alone and combined with niraparib in advanced solid tumors to assess safety and effectiveness.

What is being tested: AZD0120, a dual CAR T cell therapy targeting CD19 and BCMA, is being investigated as a potential treatment for adults…

What is being tested: M3554 is an anti-GD2 antibody-drug conjugate (ADC) being evaluated for dose optimisation and safety assessment in patients with advanced soft…

What is being tested: TT-702 is a novel drug candidate undergoing evaluation for safety, tolerability, and optimal dosing in patients with advanced solid tumours,…

CD19 CAR T-cell therapy tested for safety and effectiveness in patients with relapsed/refractory brain lymphoma.

Gene therapy SRP-1003 tested for safety and effectiveness in patients with type 1 myotonic dystrophy.

Investigational Agent: GDC-1261 is being tested for the first time in prostate cancer patients to assess its safety profile, how the body processes it…

TSRA-196 is being tested as a potential therapeutic intervention in adults with PiZZ alpha-1 antitrypsin deficiency (AATD), a serious genetic disorder causing progressive lung…

What is being tested: A combination of bexmarilimab (a CSF-1R inhibitor) with nivolumab (a PD-1 checkpoint inhibitor) in patients with advanced melanoma and non-small…

What is being tested: MGC026, a novel therapeutic agent, is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity in patients with advanced…

What is being tested: KCAT19 evaluates allogeneic T cells engineered with dual receptors (TCR-KDEL and CAR-targeting CD19) as a novel immunotherapy for advanced, treatment-resistant…

Gene therapy trial testing safety and effectiveness of DB-OTO for hearing loss caused by otoferlin gene mutations in children and adults.

Early-stage trial testing epcoritamab (new antibody) for treatment-resistant B-cell lymphoma, measuring safety, dosing, and effectiveness.

Early-stage trial testing a new drug (ALE1) for safety and effectiveness in healthy people and those with hypophosphatasia.

A radioactive drug combined with standard chemotherapy and immunotherapy is being tested in newly diagnosed extensive small cell lung cancer.

Trial testing combined amivantamab and capmatinib drugs in advanced lung cancer with specific genetic mutations to find safe, effective doses.

New drug JNJ-90009530 tested in patients with hard-to-treat B-cell lymphoma to find safe doses and whether it works.

Drug Being Tested: ART0380, a novel therapeutic agent being evaluated for safety, tolerability, and efficacy in patients with advanced or metastatic solid tumors, with…

What is being tested: MCLA-158, a bispecific antibody, is being evaluated as a single-agent treatment in patients with advanced solid tumors, with completed dose…

New drug povetacicept tested in adults with autoimmune blood disorders to assess safety and effectiveness over six months.

Early-stage trial testing safety of ARGX-119 infusions in adults with DOK7 muscle weakness syndrome.

New antibody drug (ICT01) tested alone and with pembrolizumab in advanced cancer patients to find safe doses and effectiveness.

What is being tested: MOMA-313, an oral therapeutic agent, is undergoing Phase 1 evaluation for safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity in patients…

What is being tested: INCA33890, a novel investigational agent, is undergoing a dose-escalation safety and tolerability study in patients with advanced or metastatic solid…

Trial testing ubamatamab alone or combined with cemiplimab in recurrent ovarian and other MUC16-positive cancers, assessing safety, dosing, and effectiveness.

Drug being tested: PF-08052667 is a novel investigational medicine being evaluated as monotherapy or in combination with BCG (standard intravesical immunotherapy) and/or sasanlimab (an…

What is being tested: Different dose combinations of BI 1703880 (an experimental medicine) with ezabenlimab (an existing immunotherapy) to determine tolerability and the maximum…